Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy. by Pastorek, Michal et al.
INTERNATIONAL JOURNAL OF ONCOLOGY  47:  51-60,  2015
Abstract. One of the recently emerging anticancer strategies 
is the use of natural dietary compounds, such as sulforaphane, 
a cancer-chemopreventive isothiocyanate found in broccoli. 
Based on the growing evidence, sulforaphane acts through 
molecular mechanisms that interfere with multiple oncogenic 
pathways in diverse tumor cell types. Herein, we investigated 
the anticancer effects of bioavailable concentrations of 
sulforaphane in ovarian carcinoma cell line A2780 and its two 
derivatives, adriamycin-resistant A2780/ADR and cisplatin-
resistant A2780/CP cell lines. Since tumor microenvironment 
is characterized by reduced oxygenation that induces aggres-
sive tumor phenotype (such as increased invasiveness and 
resistance to chemotherapy), we evaluated the effects of 
sulforaphane in ovarian cancer cells exposed to hypoxia 
(2% O2). Using the cell-based reporter assay, we identified 
several oncogenic pathways modulated by sulforaphane in 
hypoxia by activating anticancer responses (p53, ARE, IRF-1, 
Pax-6 and XRE) and suppressing responses supporting tumor 
progression (AP-1 and HIF-1). We further showed that sulfora-
phane decreases the level of HIF-1α protein without affecting 
its transcription and stability. It can also diminish transcrip-
tion and protein level of the HIF-1 target, CA IX, which 
protects tumor cells from hypoxia-induced pH imbalance and 
facilitates their migration/invasion. Accordingly, sulforaphane 
treatment leads to diminished pH regulation and reduced 
migration of ovarian carcinoma cells. These effects occur in 
all three ovarian cell lines suggesting that sulforaphane can 
overcome the chemoresistance of cancer cells. This offers a 
path potentially exploitable in sensitizing resistant cancer cells 
to therapy, and opens a window for the combined treatments of 
sulforaphane either with conventional chemotherapy, natural 
compounds, or with other small molecules.
Introduction
Tumors develop through the accumulation of genetic, epigen-
etic and somatic alterations that promote cell proliferation 
and survival. The expansive tumor growth then leads to 
architectural and physiological changes in the tumor tissue 
microenvironment, including a reduced oxygen delivery by 
the aberrant vasculature. Resulting hypoxia is one of the key 
drivers of cancer progression (1). It significantly affects crucial 
aspects of the tumor cell phenotype, such as metabolism, 
migration-invasion, dedifferentiation-stemness, and thereby 
supports metastasis (2). Moreover, hypoxia contributes to poor 
response of cancer patients to conventional anticancer thera-
pies (3). In many tumor types, including ovarian carcinoma, 
hypoxia supports development of resistance to many currently 
used chemotherapeutic agents (4,5). Thus, it is important to 
search for new approaches and/or agents targeting hypoxic 
tumor cells in order to achieve better anticancer effects.
One of the recently emerging anticancer strategies is 
the use of natural dietary compounds, such as sulforaphane 
(SFN). SFN is a cancer-chemopreventive isothiocyanate 
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found in cruciferous vegetables, namely in broccoli. Based 
on the growing experimental evidence, SFN acts through 
various molecular mechanisms that interfere with multiple 
oncogenic pathways and thereby induce anti-proliferative, 
anti-inflammatory, and pro-apoptotic responses in diverse 
tumor cell types (6-9). It also modulates metabolism of xeno-
biotics via induction of phase II detoxification enzymes (10). 
However, these studies were generally performed in 
normoxia and thus do not fully reflect the physiological 
situation in the tumor microenvironment. There are only 
few studies on SFN effect in hypoxic cancer cells (11-13). 
One of them, investigating the human prostate, tongue and 
colon carcinoma cells exposed to hypoxia showed that SFN 
can interfere with the HIF-1 pathway through decreasing the 
HIF-1α protein level and reducing the expression of the pro-
angiogenic growth factor VEGF (12).
HIF-1 is a master transcription factor that orchestrates 
molecular responses to hypoxia. It is composed of two subunits, 
a constitutive β-subunit and an oxygen-sensitive α subunit. 
Oxygenation of cells leads to quick inactivation and protea-
somal degradation of the HIF-1α subunit via a mechanism 
involving hydroxylation and pVHL-mediated ubiquitination. 
When oxygen level decreases these processes are inhibited, 
HIF-1α accumulates and dimerizes with HIF-1β to form the 
functional HIF-1 that binds a consensus HRE sequence in 
the promoters or enhancers of many genes mediating adap-
tive processes in hypoxic cells (14,15). The encoded proteins 
include VEGF as a mediator of tumor angiogenesis, GLUT-1 
and glycolytic enzymes as mediators of metabolic reprogram-
ming of cancer cells, CA IX as a mediator of acid-base balance 
in the tumors and many other regulatory molecules.
In this study, we focused on the effect of SFN in hypoxic 
ovarian carcinoma cells and in their chemoresistant vari-
ants. Ovarian cancer has the highest mortality among the 
gynecologic cancers. Most patients are diagnosed at a late 
stage and are usually treated by surgery followed by adjuvant 
chemotherapy. However, recurrence occurs in up to 75% of 
patients, who usually develop chemoresistance and eventually 
succumb to the disease. In ovarian carcinoma cells, hypoxia 
was correlated with poor prognosis, epithelial-mesenchymal 
transition, invasiveness, metastasis and stem-like pheno-
type (4,16,17). Moreover, HIF-1 target genes were proposed to 
predict increased resistance to chemotherapy and poor overall 
survival of ovarian cancer patients (18).
We found that in A2780 ovarian carcinoma cells exposed 
to low oxygen, SFN modifies the transcriptional program 
driven by several pathways related to hypoxia and oncogenic 
signaling. We specifically focused on the HIF pathway and 
demonstrated that SFN can reduce the protein levels of HIF-1α 
in hypoxic A2780 cells without affecting its transcription and 
stability. This results in diminished promoter activation, tran-
scription and protein levels of the HIF-1 transcriptional target 
CA IX. Moreover, these effects can be recapitulated in ovarian 
cancer cell variants A2780/ADR and A2780/CP resistant to 
adriamycin and cisplatin, respectively, suggesting that chemo-
resistance cannot abolish the SFN-mediated down-modulation 
of adaptive responses to hypoxia. Finally, we showed that 
these effects of SFN lead to reduced invasiveness of all three 
ovarian cell lines supporting the view that SFN consumption 
may have beneficial anticancer effects also in the advanced 
cancer stages characterized by the presence of hypoxic tumor 
regions and associated aggressive tumor features.
Materials and methods
Cell lines, reagents and culture conditions. The human 
ovarian cancer cell line A2780 and derived cell lines resis-
tant to adriamycin A2780/ADR and cisplatin A2780/CP 
were described earlier (19,20). The cells were cultured in 
Dulbecco's modified Eagle's medium supplemented with 
10% fetal calf serum (Bio-Whittaker, Verviers, Belgium) 
and 40 mg/ml gentamicin (Lek, Ljubljana, Slovenia) in a 
humidified atmosphere with 5% CO2 at 37˚C. Exposure to 
hypoxia was performed in an anaerobic workstation (Ruskin 
Technologies, Bridgend, Uk) in 2% O2, 5% CO2, 10% H2, 
and 83% N2 at 37˚C. Alternatively, hypoxia was mimicked 
by 1 mM dimethyloxalylglycine. Sulforaphane was obtained 
from Sigma-Aldrich (St. Louis, MO, USA) and used at 
2.5-10 µM depending on the experimental setting. The cells 
were first pre-treated with SFN for 4 h and then continuously 
incubated with SFN in normoxia and/or hypoxia for addi-
tional 24 h or for longer periods.
PCR analysis. Total RNA was extracted using the Instapure 
reagent (Eurogentec, Seraing, Belgium) as recommended by 
the manufacturer. Three micrograms of RNA was transcribed 
with a High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Foster City, CA) using random heptameric primers. 
quantitative real-time PCR was performed on a StepOne Real-
Time PCR System (Applied Biosystems) using Power SYBR 
Green PCR Master Mix (Applied Biosystems) and gene-specific 
primers (CA9, HIF-1α) and primers for β-actin that served as 
an internal standard. The primers were as follows: CA9 sense: 
5'-CCGAGCGACGCAGCCTTTGA-3' and CA9 antisense: 
5'-GGCTCCAGTCTCGGCTACCT-3'; HIF-1α sense 5'-GCT 
TGGTGCTGATTTGTGAACC-3', HIF-1α antisense 5'-GCA 
TCCTGTACTGTCCTGTGGTG-3'; β-actin sense: 5'-TCCTC 
CCTGGAGAAGAGCTA-3' and β-actin antisense: 5'-ACAT 
CTGCTGGAAGGTGGAC-3'. PCR was performed using 
DreamTaq™ Green PCR Master Mix (Fermentas, St. Leon-Rot, 
Germany) and the same primers as shown above.
Promoter analysis. Human CA9 promoter construct pGL3-
CA9 was generated by an insertion of PCR-amplified -174/+37 
CA9 genomic fragment upstream of the firefly luciferase gene 
in pGL3-Basic luciferase reporter vector (Promega, Madison, 
WI, USA). pRL-Tk Renilla vector (Promega) served as a trans-
fection efficiency control. A2780 cells were plated into 35-mm 
Petri dishes to reach approximately 70% monolayer density on 
the next day. Transient transfection was performed with 1 μg 
of pGL3-CA9 plasmid and 100 ng of pRL-Tk plasmid using 
Turbofect reagent (ThermoFisher Scientific) according to the 
manufacturer's recommendations. One day later, transfected 
cells were trypsinized and plated in triplicates into 24-well 
plates. Transfected cells were allowed to attach overnight, 
and then transferred to hypoxia for additional 24 h. SFN was 
added 4 h before the transfer to hypoxia. Reporter gene expres-
sion was assessed using the Dual Luciferase Reporter Assay 
System (Promega), and the luciferase activity was normalized 
against the Renilla activity.
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Western blot analysis. The cells were washed with PBS and 
disrupted in lysis buffer containing 1% Triton X-100, 150 mM 
NaCl, 50 mM Tris (pH 7.5), 0.5% Nonidet P-40, 50 mM NaF, 
and complete protease inhibitor cocktail (Roche, Mannheim, 
Germany). Protein concentrations were determined by bicin-
choninic acid assay (Pierce Biotechnology, Rockford, IL, USA) 
according to the manufacturer's instructions. Total protein 
extracts (50-100 mg/lane) were separated by SDS-PAGE 
under reducing conditions and blotted onto polyvinylidene 
fluoride membranes (Immobilon; Millipore, Billerica, MA, 
USA). Membranes were treated for 1 h in blocking buffer and 
then incubated either for 1 h with specific antibodies against 
CA IX (in-house generated M75 in blocking buffer, dilution 
1:2), HIF-1α (dilution 1:250; BD Transduction Laboratories, 
San Jose, CA, USA), GLUT-1 (dilution 1:1000; Cell Signaling 
Technology, Danvers, MA, USA), and actin (dilution 1:1000; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA). All 
membranes were then washed four times for 10 min with the 
washing buffer (PBS containing 0.2% Nonidet P-40 or 0.1% 
Tween-20), followed by the incubation with an appropriate 
secondary antibody conjugated with horseradish peroxidase 
(Dako, Glostrup, Denmark) for 1 h. After additional washing 
step, all immunoblots were developed with the ECL detection 
system.
Flow cytometry. Cells were harvested in concentration of 
1x106 cells/sample and washed in PBS. Labeling was performed 
in 50 µl of cell suspension with 50 µl of mouse monoclonal 
antibody M75 for 30 min. Mouse monoclonal antibody against 
CD45 was used as a negative isotype control. Cells were then 
washed and labeled with goat anti-mouse F(ab')2 antibody 
conjugated with FITC for 30 min at room temperature and 
analyzed on flow cytometer Coulter Epics Altra. Data were 
analyzed with FCS Express version 3.0 (De Novo Software, 
Ontario, Canada).
For assessment of cell viability, the cells were incubated 
with propidium iodide at a final concentration of 5 µg/ml for 
5 min at room temperature. The samples were analyzed using 
a Guava EasyCyte Plus flow cytometer with Guava Express 
Pro 2.2.3 software (Millipore).
Cignal assay. Cignal®™ Cell-based Multi-Pathway Activity 
Assay (SABioscience, Frederick, MD, USA) was performed 
according to instructions of the manufacturer. Dual-luciferase 
results were calculated for each transfectant and analyzed 
by the data analysis software (SABioscience). Changes in 
the activity of each signaling pathway were determined by 
comparing the normalized luciferase activities of the reporter 
in treated vs. untreated transfected cells.
Cell proliferation and migration assays using real-time cell 
analyzer system (RTCA). For the proliferation assay, 4x104 
A2780 ovarian cancer cells and their chemoresistant variants 
were seeded into each well of an E-plate 16 (Roche) in DMEM 
containing 5 µM sulforaphane or DMSO (control samples). 
For the migration assay, the cells were first pre-treated with 
sulforaphane or DMSO for 24 h in hypoxia and then seeded 
into the upper chamber of the CIM-plate 16 (Roche) in the 
medium containing 0.1% FCS and 5 µM sulforaphane. A 
chemotactic signal for the cell movement was provided by 
supplying 10% FCS into the lower chamber. The plates were 
placed into the real-time cell analyzer (RTCA, xCELLigence, 
Roche), performing an impedance-based, label-free moni-
toring of cell proliferation and migration. RTCA analyzer was 
placed in a hypoxic cabinet with the O2 controller (2% O2, 
COY Laboratory Product, Grass Lake, MI, USA). Data were 
collected every 15 min during the entire period of measure-
ment and were presented as a dimensionless parameter called 
the cell index (CI; calculated as a relative change in the 
measured electrical impedance), graphs show the average of 
triplicate wells.
Measurements of intracellular and extracellular pH. 
Intracellular pH (pHi) was measured using the fluorescent 
probe 2',7'-biscarboxyethyl-5,6-carboxyfluorescein (BCECF; 
Sigma-Aldrich). SFN-treated cells, untreated controls and 
cells for calibration curve were plated on 6-well plates and 
loaded with 8.2 µM BCECF and 5% pluronic acid in PBS 
buffer, pH 7.48 for 30 min at 37˚C in the dark. Afterwards, 
the cells were washed with PBS buffer and measured. 
Calibration was performed on untreated cells using 
PBS/HEPES buffers with different pH values (7.61, 7.48, 
7.03, 6.52, 6.32 and 6.01). The fluorescence was excited at 
489 nm and measured at 525 nm on the fluorescence scanner 
BioTek (BioTek, Germany). The pHi signal was calibrated by 
adding 10 µM of nigericin (Sigma-Aldrich) with 130 mM of 
kCl. pHi values for samples were calculated from the cali-
bration curve. Extracellular pH was measured in cell culture 
media as described earlier (21).
Statistical analysis. Results were analyzed by two-tailed 
unpaired t-test (Student's t-test), and P<0.05 was considered 
significant.
Results
SFN affects hypoxia-induced and oncogenic molecular path-
ways in A2780 ovarian carcinoma cells. First we investigated 
how A2780 ovarian carcinoma cells respond to hypoxia and 
SFN in a broader context of molecular pathways. We exposed 
A2780 cells for 24 h to 2% of atmospheric oxygen, which 
corresponds to moderate hypoxia typical for tumor cells 
present in broader perinecrotic areas less distant from the blood 
vessels. Western blot analysis of extracts from normoxic vs. 
hypoxic A2780 cells revealed a hypoxia-related accumulation 
of HIF-1α protein and its target CA IX suggesting that these 
cells are sensitive to reduced oxygen and react by induction of 
a canonical HIF response (Fig. 1A). The A2780 cells grown 
in a confluent monolayer were then treated with SFN for 28 h, 
including 4 h pre-treatment in normoxia followed by a 24 h 
treatment in hypoxia. Cells treated with 2.5, 5 and 10 µM 
concentrations of SFN were subjected to flow cytometric 
analysis to assess their viability. As shown on Fig. 1B, hypoxia 
alone induced 10% cell death of A2780 cells, which was only 
slightly increased by SFN treatments. Moreover, a real-time 
monitoring of the proliferation of A2780 cells did not show any 
pronounced inhibitory effect of 5 µM SFN either in normoxia 
(not shown), or in hypoxia (Fig. 1C).
Since the concentration of about 5 µM SFN is achiev-
able in vivo (22), we decided to use this SFN concentration 
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in the subsequent experiments. A cell-based reporter assay 
confirmed the hypoxia-related activation of the HIF pathway 
(Fig. 1D). In addition, exposure of A2780 cells to hypoxia 
led to the activation of the MAPk/JNk pathway executed by 
the AP-1 transcription factor, which was previously linked to 
hypoxia and VHL deficiency (23,24). SFN treatment consider-
ably reduced the reporter transactivation via HIF and AP-1 
pro-oncogenic pathways. On the other hand, five other path-
ways involved in the negative control of tumor growth were 
considerably upregulated by SFN during hypoxia, including 
the pathways resulting in activation of ARE/NRF2, p53, 
IRF-1, Pax-6 and XRE-driven transcription (Fig. 1D).
SFN reduces the HIF-1α level and activity in hypoxic 
A2780 cells without affecting its stability. We then further 
followed the HIF-1α response to SFN under hypoxia. First, 
we analyzed the SFN effect on the HIF-1α mRNA level and 
found no significant difference between SFN-treated and 
control A2780 cells exposed to hypoxia, suggesting that SFN 
did not affect the transcription of the HIF-1α gene (Fig. 2A). 
In contrast, the western blot analysis showed a considerably 
reduced level of the HIF-1α protein in the hypoxic A2780 
cells subjected to SFN treatment when compared to the 
control hypoxic cells (Fig. 2B). Since the abundance of the 
HIF-1α protein can be regulated on the level of translation 
and/or degradation, we analyzed the stability of the HIF-1α 
protein in hypoxic conditions following the inhibition of 
translation by 20 µg/ml cycloheximide (CHX). However, the 
Figure 1. Molecular and cellular response of A2780 cells to hypoxia and SFN. (A) Western blot analysis of HIF-1α and CA IX expression in A2780 cells. The 
blot shows that these proteins are absent in normoxia (No) but induced in response to hypoxia (Hy). Actin serves as a loading control. (B) Flow cytometric 
analysis of the viability of hypoxic vs. normoxic A2780 cells (control) and the parallel normoxic vs. hypoxic samples treated with increasing concentrations of 
SFN as described in Materials and methods. The graph depicting percentage of live (propidium iodide-negative) cells in population indicates only insignificant 
decrease in cell viability in all treated samples. (C) Real-time analysis of proliferation of the hypoxic A2780 cells treated with 5 µM SFN for 48 h compared 
with the non-treated controls. The graph shows the slope of cell index normalized to 6 h time point after plating at which time all cells were attached to the 
bottom of the wells of the impedance plate and hypoxia was settled at 2%. Data indicate that SFN treatment did not affect the proliferation of hypoxic A2780 
cells. (D) Cell-based dual luciferase reporter assay of hypoxic vs. normoxic A2780 cells and hypoxic A2780 cells vs. cells treated with 5 µM SFN revealed 
hypoxia- and SFN-induced alterations of several signal transduction pathways leading to changes in transactivation activities of the transcription factors 
indicated in the graph. In principle, SFN downregulated pro-oncogenic pathways (represented by HIF-1α and AP-1) and upregulated anti-oncogenic pathways 
(such as ARE/NRF2, p53, IRF-1, Pax-6 and XRE).
Figure 2. Effect of SFN on HIF-1α transcription, protein level and stability in 
A2780 cells. (A) Reverse-transcription PCR analysis of the HIF-1α transcrip-
tion in normoxic and hypoxic A2780 cells in the absence and the presence 
of SFN. β-actin was used as standard. SFN treatment did not change the 
levels of the HIF-1α transcript. (B) Western blot analysis of HIF-1α protein 
levels in non-treated hypoxic A2780 cells (Hy) and in hypoxic A2780 cells 
treated with 5 µM SFN (Hy+SFN). (C) Western blot analysis of HIF-1α 
protein stability in non-treated (Hypoxia) and in 5 µM SFN-treated hypoxic 
A2780 cells (Hypoxia+SFN) in the presence of 20 µg/ml cycloheximide 
(CHX). SFN treatment did not affect the HIF-1α level suggesting that it did 
not decrease the HIF-1α protein stability.
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levels of the HIF-1α protein were similar in the hypoxic 
A2780 cells incubated with CHX for 10 min whether or 
not they were pre-treated with SFN (Fig. 2C), indicating 
that SFN did not induce HIF-1α degradation. This supports 
the view that SFN acts through the suppression of HIF-1α 
translation.
In the next step, we analyzed the effects of SFN on the 
HIF-1α downstream target CA IX. In agreement with the 
reduced HIF-1α protein level, SFN was able to diminish the 
hypoxia-induced activation of the CA9 gene promoter almost 
to its normoxic value as determined by the dual luciferase assay 
(Fig. 3A). It could also reduce the level of the corresponding 
transcript as evident from the PCR analysis (Fig. 3B and C) 
and finally, decrease the level of the CA IX protein as seen in 
the western blot analysis (Fig. 3D). Moreover, the flow cyto-
metric analysis revealed that SFN treatment led to a reduced 
proportion of the CA IX-positive tumor cell subpopulation of 
the hypoxic A2780 cells (Fig. 3E).
SFN decreases the expression of HIF-1α and its targets 
CA IX and GLUT-1 in chemoresistant A2780/CP and A2780/
ADR cells. Drug resistance is one of the key obstacles in 
therapy of ovarian cancer, and hypoxia is known to support 
this phenomenon by activation of molecular mechanisms 
of multiple drug resistance as well as by selection of cells 
that are less responsive to drug treatment (5). Therefore, we 
evaluated the effect of SFN in the chemoresistant variants of 
A2780 cells under hypoxic conditions using the A2780/CP 
cell line resistant to cisplatin (expressing the MRP1 gene) 
and A2780/ADR cell line resistant to adriamycin (expressing 
the MDR1 gene). Of note, these chemoresistant cell lines 
showed increased HIF-1α protein levels when exposed to 
2% hypoxia similarly to parental chemosensitive A2780 
cells (Fig. 4A). This was associated also with the increased 
CA9 promoter activation (Fig. 4B), increased induction of 
the CA9 transcript (Fig. 4C) and with the elevated CA IX 
protein expression (Fig. 4A).
Noteworthy, SFN was able to reduce the molecular 
response to hypoxia in both cell lines in an extent similar to 
that in parental A2780 cells, although the inhibitory effect 
did not go back to the normoxic values either at the level 
of CA9 mRNA or at the protein levels of both HIF-1α and 
its CA IX and GLUT-1 downstream targets (see Fig. 4B-D). 
Moreover, in both chemoresistant cell lines SFN reduced the 
proportion of the CA IX-positive subpopulation of cells simi-
larly to that observed in the parental A2780 cell line (Fig. 4E 
and F). Altogether, these data suggest that SFN can exhibit its 
anticancer effect also in the chemoresistant cell lines.
SFN affects pH regulation and reduces migration of hypoxic 
A2780 cells as well as their chemoresistant variants. Since 
CA IX, cooperating with ion transporters and exchangers, is 
functionally implicated in acidification of extracellular pH 
(pHe) and in maintenance of neutral/slightly alkaline intra-
cellular pH (pHi), we evaluated the pH changes in response 
to 24 h SFN treatment. We found decreased pHi (Fig. 5A) 
and increased pHe (Fig. 5B) in SFN-treated hypoxic cells 
compared to non-treated hypoxic controls, suggesting that SFN 
Figure 3. Effect of SFN on expression of the HIF-1α target CA IX. (A) Analysis of the CA9 promoter activity in normoxic and hypoxic A2780 cells and in 
hypoxic A2780 cells treated with SFN. A2780 cells were co-transfected with pGL3-CA9 and pRL-Tk plasmids, incubated for 24 h in normoxia (No), hypoxia 
(Hy) and in hypoxia with 5 µM SFN (Hy+SFN), and analyzed by dual luciferase assay. The data show that in hypoxic A2780 cells, SFN reduced the CA9 
promoter activity almost to the normoxic level. (B) RT-PCR analysis of the CA9 transcription in normoxic and hypoxic A2780 cells in the absence and the 
presence of SFN. β-actin was used as standard. CA9 transcription was induced by hypoxia and SFN treatment led to its dose-dependent decrease. (C) This 
reducing effect of SFN was confirmed by quantitative PCR analysis. (D) Western blot analysis of CA IX protein levels in non-treated hypoxic A2780 cells (Hy) 
and in hypoxic A2780 cells treated with 5 µM SFN (Hy+SFN). (E) Flow cytometric analysis of the CA IX expression in the population of hypoxic A2780 cells. 
The histograms show hypoxic cells incubated without the primary antibody (left), hypoxic cells labeled with the CA IX-specific monoclonal antibody M75 
(middle), and SFN-treated hypoxic cells labeled with M75 (right). SFN treatment resulted in the reduced proportion of the CA IX-positive cells.
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interferes with the capacity of the pH regulating machinery of 
the parental A2780 cells as well as of both A2780/ADR and 
A2780/CP chemoresistant cell lines to maintain the proper 
acid-base balance in hypoxia.
Finally, we tested whether SFN affects behavior of 
A2780 cells and of the chemoresistant variants. Since 
tumor progression to metastasis is associated with hypoxia 
and induction of migratory phenotype (25), we examined 
the ability of SFN to modulate migration of A2780 vari-
ants. To this end we used an impedance-based approach, 
which allows for the real-time evaluation of cell migration. 
We found that SFN reduces migration of hypoxic chemo-
sensitive and chemoresistant A2780 cell lines (Fig. 6A, C, 
E and G). To exclude the contribution of cell proliferation 
to the observed effect, we simultaneously monitored this 
parameter by real-time measurement of the cells plated in 
parallel, pre-treated in hypoxia and grown on the bottom 
of impedance plates. This control experiment showed no 
differences in the proliferation cell index of the analyzed 
cell lines (Fig. 6B, D and F). Thus, we can conclude that 
SFN can diminish migration of the ovarian carcinoma cells 
that were exposed to hypoxia.
Figure 4. Responses of chemoresistant A2780/ADR and A2780/CP cells to hypoxia and SFN. (A) Western blot analysis of HIF-1α and CA IX expression in 
adriamycin-resistant A2780/ADR cells and in cisplatin-resistant A2780/CP cells. The blots show that these proteins are absent in normoxia (No) but induced 
in response to hypoxia (Hy). (B) Dual luciferase analysis of the CA9 promoter activity in A2780/ADR and A2780/CP in normoxia, hypoxia and in hypoxia 
with SFN. The data show strong increase in the CA9 promoter activity in both cell variants in hypoxia and reduction in the promoter activity in hypoxic cells 
treated with SFN. (C) RT-PCR analysis of the CA9 transcription in normoxic and hypoxic A2780/ADR and A2780/CP cells in the absence and the presence of 
SFN. β-actin was used as standard. CA9 transcription was induced by hypoxia, and SFN treatment led to its dose-dependent decrease. (D) Western blot analysis 
of non-treated hypoxic A2780/ADR and A2780/CP cells (Hy) and of hypoxic cells treated with 5 µM SFN (Hy+SFN) for expression of HIF-1α and its targets 
CA IX and GLUT-1. Actin was used as a loading control. SFN treatment led to decreased levels of all three analyzed proteins. (E) Flow cytometric analysis of 
the CA IX expression in the population of hypoxic A2780/ADR and A2780/CP cells labeled with the M75 antibody. The histograms show hypoxic cells (left) 
and SFN-treated hypoxic cells (right). SFN treatment resulted in a reduced proportion of the CA IX-positive cells. (F) The graph illustrates the cytometric 
data as the relative CA IX expression values.
Figure 5. Effect of SFN on pH regulation in A2780 cells and their chemo-
resistant variants. (A) SFN-induced changes in intracellular pH (pHi). The 
cells were loaded with SNARF and analyzed as described in Materials and 
methods. The graph shows differences in pHi in all three analyzed cell lines 
that were plated in triplicates and treated with SFN compared to control non-
treated cells. (B) SFN-induced changes in extracellular pH (pHe) measured 
in culture media of cells exposed to hypoxia for 24 h (Hy) and of hypoxic 
cells treated with SFN (Hy+SFN). The graph shows differences in pHe 
between SFN treated and non-treated cells. *p<0.05, **p<0.01, and ***p<0.001.
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Discussion
As an attractive opportunity for cancer prevention and treat-
ment, sulforaphane has been extensively studied in the context 
of its anticancer effects and targets. Although the list of the 
SFN studies is large, most of them suffer from one of two 
drawbacks. Firstly, SFN was often evaluated in high concentra-
tions that cannot be reached in vivo (10,12,26). Secondly, the 
vast majority of studies was performed in normoxia, although 
almost all solid tumors contain hypoxic areas, which are 
known to affect cell behavior and reduce response to thera-
pies (8-10,22,26). Actually, there are only a handful of studies 
describing the effects of SFN in hypoxic tumor cells (12,13,27).
Herein, we used the hypoxic A2780 ovarian cancer cells 
as a model. Ovarian tumors are characterized by the presence 
of hypoxia, aggressive behavior and resistance to therapy. 
Hypoxia affects the phenotype of ovarian cancer cells by 
inducing stem-like properties (17), migration and invasion (28) 
and reduced sensitivity to drugs (29,30). Moreover, hypoxia 
correlates with poor prognosis and weak response to therapy 
in ovarian cancer patients (4,31,32). In some of these studies, 
treatment-refractory tumors display expression of the hypoxia-
induced CA IX, which is associated with advanced cancer 
stages and poor clinical outcome (18,33-35).
We focused on the effects of SFN at 5 µM, a concentra-
tion matching with the bioavailable levels in cells exposed to 
Figure 6. Effect of SFN on migration of A2780 cells and their chemoresistant variants. Real-time impedance-based measurement of migration ability (A, C 
and E) and proliferation (B, D and F) of SFN-treated vs. non-treated hypoxic cells A2780 (A and B), A2780/ADR (C and D) and A2780/CP (E and F). Data 
collected from triplicates at 15 min intervals are expressed as cell index (A, C and E) or cell index normalized to 6-h post-plating (B, D and F). Slope of cell 
index for all three cell lines is illustrated in (G). These data show that SFN reduced cell migration without affecting cell proliferation.
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moderate hypoxia. This dose was eight-times lower than that 
used by Yao et al (12), who did not show the viability data. 
However, based on the other reports, SFN increases cell death 
in hypoxic tumor cells, especially at higher doses (13,36). On 
the other hand, Chen et al (22) used SFN at 5 µM concentration 
in normoxia and obtained only minor effect on cell survival.
In our study, moderate hypoxia slightly reduced the 
survival of A2780 cells and 5 µM SFN showed only a very 
modest effect. However, at this concentration SFN inhibited 
the HIF-related pathway and AP-1-mediated transcriptional 
activation. Since both pathways contribute to the hypoxic 
signaling, SFN clearly affects molecular responses to hypoxia. 
Simultaneously, SFN activated the pathways that nega-
tively control tumor growth and usually interfer with or are 
suppressed by hypoxia. For example, hypoxia reduces the level 
and transcriptional activity of the wt p53 (37), whereas SFN 
activates the wt p53 reporter as shown here and elsewhere (38). 
Similarly, NRF2 is usually activated as an antioxidant response 
and is modulated by hypoxia (39). However, SFN induces this 
antioxidant pathway as was shown also in other studies using 
different cellular models (40).
Furthermore, in A2780 cells SFN also induced the tran-
scriptional response via the xenobiotic-responsive element 
XRE that activates the expression of drug-metabolizing 
enzymes. Such XRE-mediated response has been associated 
with SFN in several cell types (10). This pathway is usually 
downregulated by hypoxia (41,42), so it is plausible that 
it would be upregulated with the decrease of the hypoxic 
signaling. SFN increased transcriptional activation by IRF-1 
(IFN-regulatory factor 1) acting as a tumor suppressor binding 
to upstream regulatory regions of IFN-1 and IFN-1-induced 
MHC class I genes (43). Thereby SFN can support the immune 
response against tumor cells and contribute to reduced tumor 
growth. All of these pathways were individually associated 
with SFN in earlier studies, but here we detected they simul-
taneous modulation, in agreement with the known pleiotropic 
anticancer activity of SFN.
The most prominent change induced by SFN was the down-
regulation of the HIF-1-mediated transcriptional response 
through a diminished expression of the HIF-1α protein, the 
HIF-1 subunit sensitive to oxygen. Since we did not observe 
any changes in the HIF-1α transcription and degradation, we 
propose that SFN affects its translation. This is in agreement 
with data of Yao et al (12) in hypoxic carcinoma cells derived 
from tongue and prostate. The role of SFN in regulation of the 
translational machinery in hypoxia has not been thoroughly 
investigated so far, however, its inhibitory effect on mTOR 
pathway was shown in PC3 prostate cancer cells cultivated 
under standard conditions (44). Thus, we assume that the 
ability of SFN to interfere with the protein synthesis might 
represent a general phenomenon.
HIF-1 trans-activates a multitude of genes mediating adap-
tive responses to hypoxia. The CA9 gene is one of the most 
strongly activated HIF-1 downstream targets, because the 
HIF-1-responsive element HRE is localized next to its tran-
scription start site (45). Moreover, AP-1-responsive element 
is localized just upstream of HRE and contributes to CA9 
transcription (46). On the other hand, p53 was shown to reduce 
the HIF-1-mediated induction of CA IX in connection with the 
DNA damage response in hypoxic cells (47). Similarly, XRE 
element was shown to downregulate the hypoxic induction of 
CA IX (42). Thus it is not surprising that SFN reduced the CA9 
promoter activation and transcription and the CA IX protein 
level. Of note, SFN also decreased proportion of the CA 
IX-positive cells in the population of A2780 cells suggesting 
that it eliminated the subpopulation that was most responsive 
to hypoxia. Given that hypoxia promotes the aggressive tumor 
cell phenotype, SFN appears to predominantly target the 
adaptable hypoxic cells.
CA IX is a cell surface enzyme catalyzing the conversion 
of carbon dioxide to bicarbonate ions and protons (48) and 
regulating pH in hypoxic tumor cells (21,49). This represents 
an adaptation to the hypoxia-triggered oncogenic metabolism 
largely relying on glycolysis and generating acidic metabolic 
products that have to be eliminated from tumor cells to 
preserve their intracellular pH and protect their survival (50). 
CA IX helps to accomplish this acid extrusion by speeding up 
the bicarbonate production and import through the bicarbonate 
transporters and consequently export of CO2 and protons to 
the extracellular milieu. Thereby it contributes to pericellular 
acidosis, which supports cell migration and invasion (21). 
Thus, it is not surprising that SFN, via suppressive effect on 
the CA IX expression and pH regulation, decreases the migra-
tion of A2780 ovarian carcinoma cells.
An important finding of this study is that SFN elicited 
similar effects (resulting in the downregulation of the HIF-1α 
and CA IX protein levels and in the decreased migration) also 
in chemoresistant cell lines under hypoxic conditions, namely 
in cisplatin-resistant A2780/CP cells and adriamycin-resistant 
A2780/ADR cells. Both hypoxia (and HIF-1α pathway) and 
CA IX protein have been associated with chemoresistance 
in various tumor types (51,52). The effects of hypoxia on 
resistance of tumors to chemotherapy can be attributed to: 
a) reduced diffusion of drugs to hypoxic areas; b) decreased 
proliferation of hypoxic tumor cells due to HIF-1-induced 
energy-saving pathways; c) selection of inherently resis-
tant cells with mutations in the DNA damage response; 
d) HIF-1-mediated activation of the DNA repair apparatus, 
e) HIF-1-triggered induction of genes conferring drug resis-
tance, and f) HIF-1-triggered death of cells unable to adapt to 
hypoxia. Whereas diffusion distance and selection processes 
are not relevant for the experiments in the monolayer culture, 
our experimental approach still involves the anti-proliferative 
and death-inducing effects, and adaptations modulating tumor 
cell phenotype.
Noteworthy, the hypoxia-induced promoter activation of 
the CA9 gene was higher in the chemoresistant cell variants 
compared to the parental A2780 cells (see the Figs. 3A vs. 4B) 
suggesting that chemoresistant cells are more responsive and/or 
adaptable to changes in oxygen levels. On the other hand, SFN 
(at its bioavailable concentration) was able to diminish the 
expression of both HIF-1α and CA IX, although the decrease 
did not reach the normoxic values. Thus, we assume that SFN 
can partially overcome the chemoresistance of ovarian cancer 
cells. This offers a path that can be potentially exploited in 
sensitizing resistant cancer cells to therapy, and opens a 
window for combined drug treatments of SFN either with 
chemotherapeutic drugs or with natural compounds. There 
are several examples showing improved anticancer effects of 
SFN combined with other compounds (20,22,53,54). Of note, 
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simultaneous treatment with SFN and acetazolamide, a pan-
carbonic anhydrase inhibitor that also inhibits CA IX, was 
very effective in the bronchial carcinoid cell lines both in vitro 
and in vivo (55). Our study may not only provide the explana-
tion for these observations but also show new directions for 
the rational application of SFN in anticancer strategies against 
hypoxic tumors.
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